A mathematical model has been developed for a two-step approach to cancer chemotherapy involving the use of targeted monoclonal antibody-enzyme conjugates for the selective activation of anti-cancer prodrugs. Theoretical analysis and numerical simulation are used to characterize critical parameters for intratumoral and systemic drug generation. The model suggests that the most important pharmacokinetic and clinical parameters for increased drug production in the tumor are the rate of prodrug clearance from the blood and the initial injected dose of prodrug. The physiological parameters with the most influence are the prodrug and drug permeability. The ratio of tumor to blood drug generation can best be improved by increasing the conjugate clearance from the blood and decreasing the rate at which prodrug is converted to active drug. Predictions from this model concerning intratumoral prodrug and drug levels are validated by comparison with experimental data. Finally, the effects of certain barriers to chemotherapeutic treatments including vascular heterogeneity and radially outward convection are studied. If vascular heterogeneity alone is considered, the model predicts that the highest drug levels will occur in the most poorly vascularized sections of the tumor. Howeve,r, when the effects of convection directed radially outward is considered, the highest drug levels are seen in the semi-well vascularized regions. This implies that the rapidly growing periphery of the tumor and the semi-necrotic tumor interior will receive the least amount of drug. These mathematical model predictions can lead to improved treatment protocols for this two step approach to cancer chemotherapy.
INTRODUCTION
Considerable cancer research has been directed towards the development of selective targeting strategies to improve the efficacy of chemotherapy. One such new and promising approach employs monoclonal antibody-enzyme conjugates for the activation of anti-cancer prodrugs. In this two-step approach, a mAb-enzyme conjugate that specifically binds to antigens presented on the surfaces of tumor cells is administered and is allowed to localize in the tumor and clear from the systemic circulation before treatment with a relatively nontoxic anti-cancer prodrug. Upon contact with the targeted antibodyenzyme conjugate, the prodrug is converted into an active cytotoxic drug. The advantages of this targeting strategy over that of direct antibody-drug conjugates [Pietersz ct al., 19941 include the ability of the conjugate to catalytically generate large amounts of active drug. The drug thus formed can penetrate into regions of the tumor mass that are inaccessible to the conjugate. Pharmacokinetics studies have demonstrated that mAb-enzymelprodrug combinations can result in high intratumoral drug concentrations [Bosslet et al., 19941, [Svensson et al., 19951, [Wallace et al., 19941 , pronounced anti-tumor activities in an array of pre-clinical tumor models [Siemers et al., 19971, [Springer et al., 19911, [Meyer et al., 19931, [Eccles et al., 19941, [Kerr er al., 19951 and activities in the clinic [Bagshawe and Begent, 19961. A number of factors can profoundly inf uence the therapeutic effects obtained from mAb-enzymetprodrug combinations. Solid tumors have complex geometric and physiologic properties which can cause high molecular weight agents, such as mAb-enzyme conjugates, to distribute in nonuniform manners. Vascular heterogeneity is an example of one such barrier to macromolecular drug delivery. The distance between capillary centers can vary widely in a tumor with most vessels located on the periphery [Endrich et al., 19791 . For this reason, mAbs used for cancer therapy tend to accumulate near well vascularized sections of the tumor with significantly reduced levels reaching the tumor interior.
Another barrier to intratumoral mAb-enzyme conjugate uptake results from the increased interstitial pressure inherent in the interior of tumor [Baxter and Jain, 19891 . The pressure is highest in the center of the tumor decreasing to normal levels in a thin boundary layer at the tumor periphery. The effect of this increased interstitial pressure is to drive a convective current radially outward. The convective flux acts to impede the diffusion of macromolecules in the interior of the tumor which can lead to nonuniform conjugate distribution.
Aside from the barriers to mAb-enzyme penetration, factors such as enzyme luneticc, conjugate biodistribution, binding affinity, and conjugate and prodrug doses and dosing schedule can all affect therapeutic efficacy. Because of the degree of complexity inherent in this approach, several studies have been directed towards the development of mathematical models to predict the effects of these parameters and others on the intratumoral and systemic conjugate and drug concentrations [Baxter and Jain, 1996, Baxter et al., 19921 . In previous papers, we studied in detail the first step of this twostep approach to chemotherapy. In Jackson et al, 1999a, we present a mathematical model based on the biology of human 3677 melanoma xenografts in nude mice in order to determine the biodistribution, pharmacokinetics, and intratumoral localization properties of L49-j?-lactamase fusion proteins in solid tumor masses. Analytic expressions for the total concentration of conjugate in the tumor, the time at which the concentration is maximal, and the half life of conjugate in the tissue were derived. The antibody-antigen dissociation ratio, the conjugate permeability, and the inter-capillary half distance within the tumor mass were found to strongly influence conjugate localization and retention in the tumor.
Here, we extend our previously described model for the prediction of intratumoral conjugate uptake ro include the activation of a systemically administered prodrug. The goal in modeling conjugate distribution and drug generation is to determine how intratumoral drug concentrations can be maximized and how the targeting index (TI) which measures the ratio of drug generation in the tumor to that in the blood can be improved. The model we describe takes into account many parameters that were not previously considered, such as the effects of free and bound intratumoral conjugate activation of prodrug, the trafficking of drug into and out of cells, vascular heterogeneity, and outward convection currents. The model has been shown to accurately predict drug levels within tumors of animals receiving mAb-enzymelprodrug combinations. This provides a means for determining optimal dosing strategies for treatment, and suggests future experimental directions.
MODEL DEVELOPMENT AND ANALYSIS
The two-step drug targeting strategy involving the combination of mAb-enzyme conjugates and a prodrug lends itself well to a three-compartment model formulation describing the tumor, plasma, and the normal tissues. The tumor compartment is then further subdivided into intracellular and extracellular space.
Compartmental Approach
The I !larmacokinetics outside the tumor was modele by two well-mixed compartments, the blood compartment and the peripheral compartment representing all other non-tumor, non-blood tissues. The volume of the blood compartment was taken to be 2.5 ml, which is the average volume of blood in an 18-22 g nude mouse. The conjugate and prodrug are injected directly into the blood and distribute throughout the body via reversible transfer between the blood and normal tissues. Only from the blood can the conjugate and prodrug pass through the microvessel wall and access the tumor. The tumor was considered to contain both intracellular and extracellular space. Once in the tumor compartment, the conjugate can diffuse and bind to antigens presented on cell surfaces. Once bound, the majority of the conjugate remains of the cell surface and is not internalized. The prodrug is convened to active drug in the presence of the enzyme, the drug thus formed is internalized into cells or is cleared (See Figure 1) .
Tumor Geometry
The structure of the tumor tissue was based on the conception of the tumor as equivalent to a collection of (Krogh) cylinders of tissue, each nourished by a single capillary, the collection possessing the same structure as a box of pencils [Krogh, 19191 . Each Krogh cylinder was considered to have an outer radius L equal to half the average distance between capillary centers and an inner radius p equal to the average radius of the tumor capillaries.
This geometrical description of the tumor together with the compartment approach was employed to describe the rate of change of the concentration of free and bound conjugate, prodrug, and drug in the tumor, blood, and peripheral compartments. The variables that were tracked are listed in Table I while the parameters that govern their rates of change are in Table I1 together with detailed references from which they were obtained.
Model Equations
In the microvessel, the concentration of conjugate, conjugate, prodrug, and drug respectively, and Ic,, surface area of the vessel divided by the volume E.;,, and k, are the blood eljmiltation rates for each of the cylinder. The prodrug conversion is reasonagent. The rate of transfer from microvessel to tunlor ably taken to follow Michaelis-Menton hnetics with is give by the product of the permeability and the reaction parameters represented by Vma, and Kat. where bI is included to account for any escape of the drug from inside the tumor cells. The initial concentration of the antibody-enzyme conjugate, prodrug, and drug in each compartment must be given and boundary conditions governing the behavior at the boundaries must be prescribed to complete the model. Initially, the concentration of both free and bound conjugate, prodrug, and drug in the normal tissues and in the tumor is zero:
The initial concentration of conjugate and prodrug in the blood compartment is the administered dose, Co and Po, respectively. There is no drug in the blood initially.
Here, r is the time of prodrug administration. For this study, the baseline value for T is 15 h after the injection of the antibody-enzyme conjugate.
Due to symmetry with surrounding Krogh cylinders, the net flux of all agents across the boundary of the tumor tissue, r = L, is zero:
The flux across the blood vessel wall, r = p, is driven by the concentration difference in the two compartments and is mediated by the wall permeability.
Data Analysis
By incorporation of the experimental data, a leastsquares fit for the blood clearance of the antibodyenzyme conjugate. L49-sFv-bL, [Siemers et al., 19971 into the biexponential function C = Ae-"t + ~e -' ?~ was obtained. and values for A, B, a , /3 were determined. These values were in turn used to compute the compartmental transfer coefficients klz, k2!. and C . The diffusion coefficient, D,, z = C, P, D, was assumed to depend on the molecular weight, Mcrr as a(Mw)" using published values for a and Z, [Nugent and Jain, 19841 . To compute the antigen density, Ao, the average value of the number of molecules per cell when saturated was 2.1 x lo4 (molecules/cell). The cell density was estimated as 2.83 x 10" (celllliter) [Baxter and Jain, 1991al by assuming 50% cell fraction and an average cancer cell diameter of 15 pm (cell density = (cell fraction/(4/3)rrr3). Together, these values lead to the antigen density listed in Table 111 . The average distance between capillary centers was calculated as L = where N is the average number of capillaries in every 0.25 mm2 of tissue which was determined experimentally 199C) bl. The alpha-decay rates ibr the blood clearance of the prodrug and drug were computed from the uhalf life data given in [Svensson et ul., 19951 and [Robert et al., 19821 respectively. The rate of cellular internalization was estimated based on the experimentally determined value for cellular permeability of doxorubicin [Dordal et al., 19921 . They estimated the permeability coefficient of doxorubicin for two different cell lines to be PC = 7.4 x 10-"ds.
The parameter a1 was estimated from this result as
Experimental data show that the intracellulas concentration of doxorubicin reaches a steady state [Nugent and Jain, 19841 ; dCalculated from the a-half life reported in [Svensson er al., 19951 and [Robert et 01.. 19821 ; eThis parameter was estimated using value for cellular permeability published in [Dordal et al., 19921: 'These values were obtained from experiments performed concunerltly for the pulpose of te~ting the mathematical model. after 1 -2 hours [Paul et al., 19791, [DeGregorio et ul., 19841 . The parameter, br, representing a small amount of breakdown or escape from the cell is included in the model for completeness.
Theoretical Analysis
The system was non-dimensionalized by timescale of conjugate association (= O(min)) in order to be consistent with [Jackson et al., 1999al . On the timescale of interest, diffusion of conjugate is a relatively slow process (= O(h)) making the quasi-steady limit used by many authors to analyze reaction diffusion processes inappropriate for this system. The transfer of molecules from the tumor back into the plasma is also a slow process ( x O(h)) and therefore these terms can be neglected to first order. The nondimensionalization and the resulting equations can be found in Appendix I. Note that the equations governing the first step of treatment, conjugate localization, are decoupled from the equations describing the prodrug administration and subsequent drug production. In [Jackson et al., 1999a1 , we studied this decoupled system in detail using singular perturbation techniques to derive a uniformly valid solution. Slow diffusion on the timescale of interest results in a small parameter e = (Dc/k,Ao~') x 0.1. To first oder, with the reaction in equilibrium, it was determined that the concentration of free conjugate in tumor can be approximated by where .cul(t) = Ae-6' + Be-Flt representing a bolus injection into the blood, , u = (Y/(1 + I/()), and 3 = tP/Lka Ao).
To analyze the prodrug and drug dynamics in the blood the following simplifying assumptions were made.
Clearance is so rapid that levels are not measurable in the normal tissues leaving only blood elimination and procluction~conversion in the equations. Experiments conducted for this study show that levels of prodrug (CDox) and drug (Dox) in the blood fall below measurable quantities as early as two hours post-injection [Paul et al., 19791, [DeGregorio et a/., 19841 . where the plasma dynamics are assumed to behave as zz Be-t2t which represent the long time behavior of conjugate elimination from the blood. We do this because in wl = Ae-clt + Be-Fzt, El >> &, and prodrug administration occurs hours or days after conjugate administration making the first exponential negligible. If the first term of the asymptotic expansion is used to approximate the integral, the solutions become
In the tumor, the same assumption relating the initial injected dose of prodrug, PO to the enzyme kinetic parameter K,tr is imposed as well as the assumption that (br/K.~l) << 1 resulting in
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These for the concentrations of prodrug and dmg in the tumor decouple from the dynamics except at the capillary tissue interface. ~l~~, the equation for the prodrug concentration (the first of (16)) is independent of the concentration of drug in the tumor (the second of (16)). An"-lytical so\utions for the prodrug concentration in the tumor can be derived for certain special cases; unfortunately such analytical soluti~ns are of little use (except in obtaining numerical values for the intratumoral prodrug and drug As with the conjugate, the prodrug concentrations in the t u o r decrease with inter-capillary half distance and this dependence is less significant over time (figure 4). Drug levels, on the other hand, are higher in poorly vascularized tissue and reflect more strongly the conjugate distribution. Again, 
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Intercapillary half distance, L (mm) FIGURE 4 Dependence of prodrug and drug concentrations in the tumor on the inter-capillary half distance, L. The levels were measured one hour post prodrug administration. The parameters used in this simulation are given in Table 111. this dependence on the inter-capillary half distance diminishes over time. Figure 4 shows the dependence of both prodrug and drug concentrations in the tumor on the inter-capillary half distance when level are measured one hour post injection.
The time of prodrug administration also affects the drug concentration in both the blood and the tumor. The drug concentration in the blood and in the tumor at various times after prodrug administration are shown in Figure 5 . With a short time delay between conjugate and prodrug administration, blood levels of conjugate are higher leading to much higher drug concentrations in the blood ( Figure 5A ). The longer the delay, the lower the drug concentration in the blood. In the tumor, however, the dependence on the time of prodrug administration is less significant ( Figure 5B ). The levels of drug are only moderately higher when the delay between conjugate and prodrug administration is short.
Critical Parameters for Increased Intratumoral Drug Production
The effect of each parameter (E) on the area under the curve (AUCj of intratumoral dmg concentrations over time was investigated by calculating EAUr = ((AUC2 -AUClI2j/AUC). Here AUC is the area under the curve when all parameters have their baseline values listed in Table 111 , AUC:: and AUCIp are the areas under the curve associated with reducing by half and doubling each parameter respectively. The baseline AUC when , parameters have the values listed in Table I11 was  3.3 x Mh-I . The results of these simulations are listed in Table 1V . prodrug administration The dependence on this delay is more pronounced for drug level in the blood and less significant intratumoral drug production. The parameter used in this simulation are given in Table 111. T, .: most significant pharmacokinetic parameter for intratumoral drug production was the rate of prodrug clearance from the blood, &,. Reducing prodrug blood clearance allows more prodrug to enter the tumor mass and results in higher drug concentrations over time. The dominant clinical parameter was the initial injected dose of prodrug, Po. As expected, higher initla1 doses leads to higher intratumoral drug concentrations. Increasing the initial injected dose of conjugate has the same effect, however less pronounced. The enzyme kinetic parameters also play a role, in that increasing the prodrug conversion rate, V, , , results in higher drug concentrations over time.
Of all the physiological parameters tested, the prodrug (Pp) and drug (PD) permeability had the most pronounced effect on the AUC in the tumor. Increasing the prodrug permeability and therefore allowing more to penetrate the capillary and enter the tumor leads to higher drug levels in the tumor. In contrast, decreasing the drug permeability and thus trapping the agent in the tumor results in significantly higher values for the intratumoral drug AUC'.
It is particularly important to consider the targeting index (TI = (AUCt,,or/AUCb~,od)) which measures the overall exposure to drug and how well the drug is targeting the tumor. The effect of each parameter on the (TI) was investigated and the results are presented in Table V . Of all the parameters tested, the rate at which the conjugate is eliminated from the blood (k,) had the most influence on the targeting index. Clearing the conjugate from the blood dramatically increases TI. Increasing the drug elimination rate in the blood (&,) will have similar effects, however less pronounced. Decreasing the initial injected dose of conjugate, Co, and the enzyme conversion parameter V,,, can aAVC1,2 and AUC2 are the areas under the average drug concentration vs. time curve associated with reducing by half and doubling, respectively, the specific parameter bsted; bTo measure the effect of each parameter on the area under the average drug concentration vs. time curve in the tumor, the ratio E = ((AUC? -AUCI;2)/AUCI) was computed, where AUC, = 3.3 x 10.' hl h-' is the area under the curve when all parameters have their baseline values. The larger the dev~ation from zero, the more significant the parameter greatly increase TI due to the reduced levels of drug produced in the blood.
Correlation Between the Mathematical Model and the Experimental Data
In order to validate the mathematical model, in vivo studies were undertaken to determine the intratumoral and blood quantities of prodrug and drug in mice that had subcutaneous 3677 human melanoma tumor xenografts. At a point when the tumors were approximately 250 mm3 in size, the animals were treated with a single bolus injection of 4 mgkg of L49-sFv-bL, a recombinant fusion protein [Siemers et ul., 19971 that binds to cell surface antigens on the melanoma tumor implants. After waiting 15 h for tumor localization and blood clearance to occur. the prodrug CDox was administered at a dose of 80 mgkg. At various time points, the tumors and blood were removed and extracted. The amount of Dox and CDox was measured by high pressure liquid chromatography according to a previously published procedure [Svensson et ul., 19951 . The data obtained were compared to the mathematical model simulations and an excellent correlation was found to exist for prodrug levels in the tumor and in the plasma; as well as for drug levels in the plasma ( Figure 6A, 6B, 6C) . The model also captures the long time experimental profiles for drug concentration in the tumor ( Figure 6D ). The discrepancy in the short time behavior might be the result of several factors including the fact that the rate drug generation may be different in the tissue.
TUMOR HETEROGENEITY
Until now, the tumor has been assumed to be a homogeneous collection of Krogh tissue cylinders with average distance between capillary centers of L = 0.2 mm. This average does not account for the fact that the intercapillary half distance can vary widely within a solid tumor mass. In addition to the structural heterogeneity, a series of papers by Baxter and Jain presented mathematical models that showed how the absence of lymphatics in tumors, combined with high tumor vascular hydraulic conductivity, leads to high interstitial pressure in the tumor interior, decreasing to the level of the surrounding tissue in a thin boundary layer at the tumor periphery [Baxter and Jain, 19891 . This high interior pressure has two effects: ( I ) a greatly reduced pressure difference for interior vessels, leading to very low convective transport (i.e. diffusive flux is the only mechanism for transport of macromolecules across vessel walls), (2) a convective current directed out of the tumor. This suggests that convection acts to impede the diffusion of macromolecules into the tumor.
The interstitial pressure boundary layer is estimated to be about 0.03 cm [Baxter and Jain, 19891 which correlates to the well vascularized layer on the outer edge of the tumor that is estimated to be 0.01-0.02 cm thick in [Endrich et al., 19791 (See Figure 6) . In this section the previous mathematical model in (1-11) is adapted to include these features inherent in tumor's structure and composition by adding a term for the convective flux of conjugate, prodrug, and drug directed out of the tumor. The resulting model equations can be found in Appendix 11. An expression for the interstitial convective velocity within an isolated tumor, c, was derived in [Baxter and Jain, 19891 . The authors made use of Darcy's law for flow through a porous medium and a continuity equation for steady-state incompressible flow to obtain an equation for the interstitial pressure. From this they determined the interstitial velocity to behave as a cash QTIR -R sinh a r / R sinh cu where K is the hydraulic conductivity of the interstitium (cm2/mm Hg-sec), p, is the effective vascular pressure (mm Hg), p, is the interstitial fluid pressure in the surrounding normal tissue (mm Hgi, and a is a dimensionless ratio relating interstitial to vascular fluid flow.
We consider a spherical tumor consisting of a heterogeneous collection of Krogh tissue cylinders. The radius of the tumor is taken to be R = 3.5 mrn giving a total volume of 180 mm3 which correlates to the size of the tumors at the initiation of treatment in [Kerr et al, 19951 . The tumor is divided into three regions, a well vascularized periphery, an intermediate region of average vascularity, and a semi-necrotic center. The convective velocity will differ in each region of the tumor and we use equation (18) have average L and c values and cylinders from the semi-necrotic region with few blood vessels in addition to the high interstitial pressure (Region C. r f = 0 -0.9 mm) have large distances between capillaries and larger convection velocities.
Numerical Simulations
The effects of tumor heterogeneity and increased interstitial pressure on the localization and retention of conjugate in the tumor were initially investigated. Table VI shows the parameter values used in the numerical simulation for each region of the tumor.
Parameters that are not mentioned were given their baseline values listed in Table 111 . Recall, that regions of poor vascularity tend also to be regions of increased interstitial pressure. The fact that the pressure in the tissue is higher than that in the capillasy leads to a convective current directed out of the tumor. This suggests that convection acts to impede the diffusion of macromolecules into the tumor. Figure 8 shows the effects of vascular heterogeneity and outward convection on intratumoral conjugate concentrations. Numerical simulations show that increased interstitial pressure and convection can lead to 70-90% less conjugate in the interior of the tumor than observed when convection is ignored. This prediction of the model is readily testable for certain fluorescent drugs such as doxorubicin as its location in the tumor can easily be detected. It is clear that vascular heterogeneity and increased interstitial pressure can significantly affect the concentration of conjugate in the tumor. The effect of these properties on drug generation and retention is also noteworthy. Figure 9 shows the drug concentration profiles in a cross section of the
Radial distance, r' (mm) FIGURE 8 Conjugate concentration profiles through a cross-section of a spherical tumor when both vascular heterogeneity and outward convection are considered. Region A is well vascularized with no outward convection, region B is semi-well with small outward convection vascularized, and region C is semi-necrotic with large outward convection.
FIGURE 9 Drug concentration profiles through a cross-section of a spherical tumor when both vascular heterogeneity and outward convection are accounted for. Region A is well vascularized with no outward convection, region B is semi-well with small outward convection vascularized, and regiou C is semi-necrotic with large outward convection.
tumor when vascular heterogeneity and the effects of increased interstitial pressure are included. The numerical simulations predict that it is not the well vascularized or the semi-necrotic regions, but the section of average vascularity that will receive the greatest exposure to the drug. Experiments have not been performed on this two-step treatment to determine which section of the tumor receive the most drug, therefore we suggest this as a future direction of experimental investigation.
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$15
; 5 -
The use of mAb-enzyme conjugates for selective prodrug conversion has resulted in promising activities both preclinically [Siemers et al., 19971, [Springer et al., 19911, [Meyer et al., 1993, Eccles et al., 1994, Ken et al., 19951 and clinically [Bagshawe and Begent, 19961 . Conjugate tumor localization and retention is critical for the targeting efficacy in many mAb-based targeting strategies including the two-step strategy described here. A 0 0
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mathematical model that encapsulates the effects that many of the physiological and biochemical parameters have on intratumoral uptake of a mAbenzyme conjugate has previously been reported [Jackson et al., 1999al . This continuation study focuses on prvdrug treatment after conjugate administration. A mathematical model is developed that describes the conversion of prodrug to active drug in the tumor, blood, and normal tissues, and the intracellular drug concentrations in the tumor.
Mathematical modeling of prodrug activation produced several significant results. Our model differs in a number of ways from previous studies [Baxter and Jain, 1996, Baxter er al., 19921 , including the fact that it accounts for the internalization of drug by the tumor cells. This proved crucial for predicting the experimental results. Simulation of the mathematical model showed that there are seve-L ral parameters that can significantly influence intra-I tumoral drug production including conjugate and prodrug dose, clearance from the blood, and prodrug and drug permeability. Of these parameters, conjugate and prodrug dose and prodrug and drug
permeability have the potential to be experimentally controlled. Optimally the prodrug should be designed to be highly permeable leading to increased amounts in the tumor. The released drug should be trapped in the tumor either due to intracellular uptake or to chemical instability.
The targeting index, T I , which measures the ratio of drug production in the tumor to that of the blood can also be significantly improved by varying certain parameters. Conjugate and drug clearance from the blood were most influential in improving this ratio. Decreasing the initial injected dose of conjugate and enzyme conversion parameter, V,,,, also results in less drug generation in the blood and therefore higher values of T I . To counteract a low, V&,, a larger dose of prodrug must be administered which also has a positive affect on T I . This finding is consistent with studies of [Baxter and Jain, 19961. Finally, two specific obstacles for the delivery of macromolecules to solid tumors were considered. Vascular heterogeneity and outward convection are investigated together and were found to have a pronounced affect on the conjugate and drug concentrations throughout a nonuniform tumor. For example, there is a 70-90% decrease in the conjugate levels seen in certain sections of the tumor. The most dramatic,!lly different results are in the drug concentration When increased convection out of the tumor is considered, no longer are the highest levels of drug seen in the poorly vascularized regions of the tumor, but it is the section with average vascularity that maintains the highest levels of conjugate.
One of the most widely tested drug targeting strategies involves the use of direct mAb-drug conjugates [Pietersz et al.. 19941 . The distribution of such conjugates within tumors would be expected to resemble that of the mAb-enzyme conjugates described here, since both are macromolecules having similar physical characteristics. In cases where the cytotoxic agent is directly appended to the mAb, the diminishing conjugate concentration deep within the tumor mass undoubtedly will have a pronounced effect on therapeutic efficacy. This concentration gradient may contribute significantly to the lack of clinical efficacy generally observed with direct mAb-drug conjugates used for solid tumor therapy [Pietersz et al., 19941 . The two-step approach described here may circumvent this problem, since the antigen bound mAbenzyme conjugate is used to catalytically generate low molecular weight drugs that can then readily diffuse into the tumor mass. Although the use of mAbenzyme conjugates for prodrug conversion remains largely untested in humans, the mathematical model points to some significant advantages and clinical promise.
APPENDIX I: NONDIMENSIONALIZATION
The system of equations (1 -11) were nondimensionalized with the following rescaling
The resulting non-dimensional equations are The convective velocity will differ in each region of the tumor and we use equation (18) to determine estimates for the velocity at different radial positions.
